4.6 Article

Long-Term Effect of Weight Loss on Obstructive Sleep Apnea Severity in Obese Patients with Type 2 Diabetes

Journal

SLEEP
Volume 36, Issue 5, Pages 641-649

Publisher

OXFORD UNIV PRESS INC
DOI: 10.5665/sleep.2618

Keywords

Apnea-hypopnea index; polysomnogram

Funding

  1. National Institutes of Health NHLBI [HL070301]
  2. National Institutes of Health NIDDK [DK60426, DK56992, DK057135]
  3. NIH
  4. CDC
  5. USDA
  6. Robert Wood Johnson Foundation
  7. Nutrisystem American Beverage Association
  8. Novo-Nordisk
  9. JennyCraig
  10. Philips Respironics
  11. Abbott
  12. Actelion
  13. Ancile
  14. Apnex
  15. Arena
  16. Aventis
  17. Cephalon Inc
  18. CHDI
  19. Elan
  20. Epic
  21. Evotec
  22. Forest
  23. Galderma
  24. Glaxo Smith Kline
  25. H. Lundbeck A/S
  26. King
  27. Merck and Co.
  28. National Institute of Health (NIH)
  29. Neurim
  30. Neurocrine Biosciences
  31. Neurogen
  32. Organon
  33. Orphan Medical
  34. Otsuka
  35. Pfizer
  36. Predix
  37. Respironics
  38. Sanofi-Aventis
  39. Sanofi-Synthelabo
  40. Schering-Plough
  41. Sepracor
  42. Shire
  43. Somaxon
  44. Takeda Pharmaceuticals North America
  45. Targacept
  46. Thymon
  47. Transcept
  48. UCB Pharma
  49. Vanda
  50. Wyeth-Ayerst Research
  51. NutriSystem

Ask authors/readers for more resources

Study Objectives: To examine whether the initial benefit of weight loss on obstructive sleep apnea (OSA) severity at 1 year is maintained at 4 years. Design: Randomized controlled trial with follow-up at 1, 2, and 4 years. Setting: 4 Look AHEAD clinical centers. Participants: Two hundred sixty-four obese adults with type 2 diabetes and OSA. Interventions: Intensive lifestyle intervention with a behavioral weight loss program or diabetes support and education. Measurements: Change in apnea-hypopnea index on polysomnogram. Results: The intensive lifestyle intervention group's mean weight loss was 10.7 +/- 0.7 (standard error), 7.4 +/- 0.7, and 5.2 +/- 0.7 kg at 1, 2, and 4 years respectively, compared to a less than 1-kg weight loss for the control group at each time (P < 0.001). Apnea-hypopnea index difference between groups was 9.7 +/- 2.0, 8.0 +/- 2.0, and 7.7 +/- 2.3 events/h at 1, 2 and 4 years respectively (P < 0.001). Change in apnea-hypopnea index over time was related to the amount of weight loss (P < 0.0001) and intervention, independent of weight loss (P = 0.001). Remission of OSA at 4 years was 5 times more common with intensive lifestyle intervention (20.7%) than diabetes support and education (3.6%). Conclusions: Among obese adults with type 2 diabetes and OSA, intensive lifestyle intervention produced greater reductions in weight and apnea-hypopnea index over a 4 year period than did diabetes support and education. Beneficial effects of intensive lifestyle intervention on apnea-hypopnea index at 1 year persisted at 4 years, despite an almost 50% weight regain. Effect of intensive lifestyle intervention on apnea-hypopnea index was largely, but not entirely, due to weight loss.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available